Statement from FDA on continuing efforts to maintain its strong oversight of generic drugs
date:Feb 25, 2019
es payer claims data. Based on an evaluation of the potential safety concern, the FDA may take regulatory action(s) to improve product safety and protect the public health, such as updating a products labeling information, restricting the use of the drug, communicating new safety information to the public, or, in rare cases, removing a product from the market.

FACT: FDAs inspectional footprint is robust, particularly in China and India

The FDA maintains global vigilance through a risk-based in

06/19 21:16